(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 June 2023 (15.06.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/107979 A1

(51) International Patent Classification:
C07D 403/14 (2006.01) *C07D 405/14* (2006.01)
C07D 487/04 (2006.01) *C07D 417/14* (2006.01)
C07D 471/04 (2006.01) *C07D 413/04* (2006.01)
A61K 45/06 (2006.01) *C07D 401/14* (2006.01)

(21) International Application Number:
PCT/US2022/081059

(22) International Filing Date:
07 December 2022 (07.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/287,456 08 December 2021 (08.12.2021) US

(71) Applicant: **KINNATE BIOPHARMA INC.** [US/US]; 12830 El Camino Real, Suite 150, San Diego, California 92130 (US).

(72) Inventors: **FRANOVIC, Aleksandra**; 12830 El Camino Real, Suite 150, San Diego, California 92130 (US). **VASSAR, Angie**; 12830 El Camino Real, Suite 150, San Diego, California 92130 (US). **MILLER, Nichol**; 12830 El Camino Real, Suite 150, San Diego, California 92130 (US). **KOBAYASHI, Ken**; 12830 El Camino Real, Suite 150, San Diego, California 92130 (US). **WILLIAMS, Richard Thomas**; 12830 El Camino Real, Suite 150, San Diego, California 92130 (US). **TYHONAS, John**; 12830 El Camino Real, Suite 150, San Diego, California 92130 (US). **KANIA, Robert**; 12830 El Camino Real, Suite 150, San Diego, California 92130 (US). **COX, Jason M.**; 12830 El Camino Real, Suite 150, San Diego, California 92130 (US). **TIMPLE, Noelito**; 12830 El Camino Real, Suite 150, San Diego, California 92130 (US). **MARTIN, Eric S.**; 12830 El Camino Real, Suite 150, San Diego, California 92130 (US). **MURPHY, Eric A.**; 12830 El Camino Real, Suite 150, San Diego, California 92130 (US).

(74) Agent: **CLARK, David**; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,

(54) Title: TREATMENT OF CANCER WITH AN FGFR KINASE INHIBITOR




FIG. 1C

(57) Abstract: Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise an FGFR kinase inhibitor. Some embodiments comprise combination therapy featuring the FGFR kinase inhibitor with at least one oncology therapeutic agent.

[Continued on next page]

WO 2023/107979 A1

KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*